CoChat

Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta‐Analysis

Open access
Konwar, Mahanjit, Bose, Debdipta, Jaiswal, Sanjeet Kumar, Maurya, Mitesh kumar, Ravi, Renju · 2022 · International Journal of Clinical Practice

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Background. Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction. Objectives. Objectives are to evaluate the efficacy and safety of liraglutide 3.0 mg in patients with overweight and obesity irrespective of diabetic status. Methods. We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m 2) and obese (≥30 kg/m 2) patients above 18 years of age. Results. We compared the pooled estimate of the study results between liraglutide 3.0 mg groups and placebo groups both in diabetic and nondiabetic patients. The efficacy outcomes that were found to be significant among respective studies involving nondiabetic patients vs. diabetic patients were mean change in body weight from baseline: 12 studies [MD = −5.04 kg (95% CI = −5.60, −4.49), P < 0.001, I2 = 92.95%] vs. 2 studies [MD = −4.14 kg (95% CI = −4.95, −3.32), P < 0.001, I2 = 0%], reduction in waist circumference from baseline: 8 studies [MD = −3.64 cm (95% CI = −4.43, −2.85), P < 0.001, I2 = 96.5%] vs. 2 studies [MD = −3.11 cm (95% CI = −3.88, −2.34), P < 0.001, I2 = 0%], BMI reduction from baseline: 5 studies [MD = −1.95 kg/m 2 (95% CI = −2.22, −1.68) vs. 1 study [MD = −1.86 kg/m 2 (95% CI = −2.14, −1.57), P < 0.001, I2 = 0%, P < 0.001, I2 = 95.6%], proportion of patients losing more than 5% of weight loss from baseline: 8 studies [RR = 2.21, (95% CI = 1.89, 2.58), P = 0.03, I2 = 59.02%] vs. 2 studies [RR = 2.34, (95% CI = 1.93, 2.85), P = 0.39, I2 = 0.00%], and 10% weight loss from baseline: 7 studies [RR = 3.36, (95% CI = 1.92, 5.91), P = 0.00, I2 = 87.03%] vs. 2 studies [RR = 3.64, (95% CI = 2.46, 5.40), P = 0.81, I2 = 0.00%]. Safety outcome assessment with use of liraglutide 3.0 mg compared with placebo in respective nondiabetic vs. diabetic patients revealed significant proportion of patients experiencing the adverse events: 9 studies [RR = 1.11, (95% CI = 1.04, 1.18), P = 0.00 I2 = 79.15%] vs. 2 studies [RR = 1.06, (95% CI = 1.01, 1.11), P = 0.42, I2 = 0.03%] but similar risk of serious adverse events: 9 studies [RR = 1.03, (95% CI = 0.70, 1.51), P = 0.26, I2 = 18.54%] vs. 2 studies [RR = 1.11, (95% CI = 0.67, 1.84), P = 0.25, I2 = 23.77%] and TDAEs: 4 studies [RR = 0.89, (95% CI = 0.35, 2.28), P = 0.03, I2 = 61.89%] vs. 1 study [RR = 2.53, (95% CI = 1.00, 6.37)]. However, the pooled estimates irrespective of the glycaemic status were mean change in body weight from baseline: 14 RCT [MD = −4.91 kg (95% CI = −5.43, −4.39), P < 0.001, I2 = 92.35%], reduction in waist circumference from baseline: 10 studies [MD = −3.55 cm, (95% CI = −4.21, −2.89), P < 0.001, I2 = 94.99%], BMI reduction from baseline: 6 studies [MD = −1.86 kg/m 2, (95% CI = −2.14, −1.57), P < 0.001, I2 = 96.14%], and proportion of patients losing more than 5% and 10% of weight from baseline: [RR = 2.23, (95% CI = 1.98, 2.52), P < 0.001, I2 = 48.87%] and [RR = 3.28, (95% CI = 2.23, 4.83), P < 0.001, I2 = 78.98%], respectively. Also, the proportion of patients experiencing the adverse event was more with liraglutide 3.0 mg compared with placebo 11 study [RR = 1.09, (95% CI = 1.04, 1.15), P < 0.01, I2 = 76.60%] and similar risk for both serious adverse events: 11 studies [RR = 1.09, (95% CI = 1.04, 1.15), P < 0.01, I2 = 76.60%] and TDAEs: 5 studies [RR = 1.14, (95% CI = 0.50, 2.60), P < 0.01, I2 = 64.93%] with liraglutide compared with placebo. Conclusions. Liraglutide in 3.0 mg subcutaneous dose demonstrated significant weight reduction with a reasonable safety profile for patients with overweight or obesity regardless of diabetic status compared to placebo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2022/1201977

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Database searches.
Figure 1 Database searches.CC BY · PubMed Central
Figure 2 Risk of bias.
Figure 2 Risk of bias.CC BY · PubMed Central
Figure 3 Mean change in body weight (kg).
Figure 3 Mean change in body weight (kg).CC BY · PubMed Central
Figure 4 Mean change in waist circumference (cm).
Figure 4 Mean change in waist circumference (cm).CC BY · PubMed Central
Figure 5 Mean change in BMI (kg/m2).
Figure 5 Mean change in BMI (kg/m2).CC BY · PubMed Central
Figure 6 5% weight loss.
Figure 6 5% weight loss.CC BY · PubMed Central
Figure 7 10% weight loss.
Figure 7 10% weight loss.CC BY · PubMed Central
Figure 8 Adverse events.
Figure 8 Adverse events.CC BY · PubMed Central
Figure 9 Serious adverse events.
Figure 9 Serious adverse events.CC BY · PubMed Central
Figure 10 Treatment discontinuation due to adverse events.
Figure 10 Treatment discontinuation due to adverse events.CC BY · PubMed Central
Figure 11 Funnel plot. (a) Mean change in body weight. (b) Mean change in waist circumference. (c) 5% weight loss. (d) Adverse events. (e) Serious adverse events.
Figure 11 Funnel plot. (a) Mean change in body weight. (b) Mean change in waist circumference. (c) 5% weight loss. (d) Adverse events. (e) Serious adverse events.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 2

  1. 2021 https://training.cochrane.org/handbook/current/chapter-08.
  2. https://training.cochrane.org/handbook/current/chapter-13.

Cited by

See all 41

Metadata

Authors
Konwar, M., Bose, D., Jaiswal, S. K., Maurya, M. K., & Ravi, R.
Affiliations
  • King Edward Memorial Hospital and Seth G.S. Medical College (IN)
  • Jazan University (SA)
Corresponding author
Ravi, Renju
Venue
International Journal of Clinical Practice
Publisher
Wiley
Published
2022-01
Volume
2022
Issue
1
Pages
1201977-1201977
ISSN
  • 1368-5031 (ISSN-L)
  • 1742-1241
OpenAlex
W4286213365
Cited by
41
References
47
Citations by year
2026: 7 · 2025: 13 · 2024: 10 · 2023: 8 · 2022: 3
FWCI
1.22
Type
journal article
Language
en
Open access
Locations
  • International Journal of Clinical Practice (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
liraglutide, GLP-1 receptor agonists, obesity, overweight, weight loss, type 2 diabetes, waist circumference, BMI reduction, adverse events, drug safety, placebo comparison
MeSH terms
Liraglutide, Diabetes Mellitus, Humans, Obesity, Weight Loss, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta‐Analysis. https://app.cochat.ai/papers/10.1155/2022/1201977
The paper
Konwar, M., Bose, D., Jaiswal, S. K., Maurya, M. K., & Ravi, R. (2022). Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta‐Analysis. International Journal of Clinical Practice. https://doi.org/10.1155/2022/1201977

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.